BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July

Day

• 1
• 2
• 3
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 27
• 28
• 29
• 30
• 31

• Skye Bioscience Provides 2025 Look Ahead and Year in Review

  January 14, 2025

   · 

  7 min read
• Press Releases

  CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

  January 14, 2025

   · 

  13 min read
• Press Releases

  Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

  January 14, 2025

   · 

  19 min read
• Press Releases

  Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD

  January 14, 2025

   · 

  5 min read
• Press Releases

  Chimerix to Speak Today at The White House Cancer Moonshot Forum

  January 14, 2025

   · 

  3 min read
• Press Releases

  EyePoint Provides Company Update and Anticipated Development Milestones for 2025

  January 14, 2025

   · 

  11 min read
• Press Releases

  Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

  January 14, 2025

   · 

  18 min read
• Press Releases

  Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

  January 14, 2025

   · 

  2 min read
• Press Releases

  X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

  January 14, 2025

   · 

  8 min read
• Press Releases

  Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

  January 14, 2025

   · 

  4 min read